🔗 Share this article

Chancellor Rachel Reeves has stated she is planning "focused measures to deal with household expense pressures" in the upcoming financial statement.

During an interview with media outlets, she stated that curbing price rises is a collective responsibility of both the government and the central bank.

The United Kingdom's price growth is expected to be the most elevated among the Group of Seven advanced economies this year and the following year.

Potential Utility Bill Measures

Sources suggest the government could intervene to lower energy bills, for instance by reducing the current 5% rate of VAT applied on energy supplies.

An additional approach is to reduce some of the policy costs currently added to household expenses.

Fiscal Constraints and Expert Predictions

The administration will obtain the next assessment from the official forecaster, the OBR, on the start of the week, which will reveal how much scope there is for such actions.

The consensus from most economists is that Reeves will have to introduce higher taxes or expenditure reductions in order to fulfill her declared debt limits.

Previously on the same day, analysis suggested there was a £22bn shortfall for the Treasury chief to fill, which is at the more modest range of expectations.

"There's a shared job between the Bank of England and the administration to bear down further on some of the drivers of price increases," the Chancellor told reporters in Washington, at the conferences of the IMF and World Bank.

Tax Pledges and Global Issues

While a great deal of the focus has been on expected tax increases, the chancellor said the most recent information from the OBR had not altered her commitment to campaign commitments not to increase tax levels on earnings tax, sales tax or National Insurance.

She blamed an "unpredictable world" with increasing international and commercial concerns for the Budget revenue measures, probably to be targeted on those "with the broadest shoulders."

International Trade Tensions

Referring to concerns about the UK's economic relations with the Asian nation she said: "The UK's national security always take priority."

Last week's statement by Chinese authorities to tighten trade restrictions on critical minerals and other materials that are essential for advanced tech manufacturing led US President Donald Trump to threaten an extra 100% import tax on imports from China, increasing the possibility of an full-scale trade war between the two largest economies.

The US Treasury Secretary described China's move "economic coercion" and "a global supply chain power grab."

Asked about accepting the American proposal to join its conflict with the Asian nation, the Chancellor said she was "very concerned" by Chinese actions and called on the Beijing authorities "to avoid restrictions and limit trade."

She said the decision was "harmful for the global economy and creates additional obstacles."

"I believe there are areas where we should address China, but there are also valuable opportunities to export to China's economy, including banking sector and other areas of the economic system. We've got to get that balance correct."

The chancellor also affirmed she was collaborating with other major economies "regarding our own essential resources strategy, so that we are less reliant."

Health Service Drug Costs and Investment

Reeves also acknowledged that the cost the National Health Service spends on drugs could rise as a consequence of ongoing negotiations with the Trump administration and its drugs companies, in return for reduced taxes and investment.

Some of the biggest global pharmaceutical manufacturers have said in recent statements that they are either pausing or canceling projects in the United Kingdom, with some attributing the insufficient payments they are obtaining.

Last month, the Science Minister said the price the NHS spends on medicines would have to rise to halt firms and drug research funding departing from the UK.

Reeves stated to the BBC: "It has been observed because of the pricing regime, that clinical trials, innovative medicines have not been offered in the United Kingdom in the extent that they are in other EU nations."

"The objective is to guarantee that individuals receiving treatment from the National Health Service are able to access the best life-saving medicines in the globe. And so we are examining this situation, and... seeking to obtain more funding into the UK."